Search En menu ClientConnect
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20140665
    Release date: 3 December 2014

    Promoter – Financial Intermediary




    The project covers the promoter’s research activities in treatment vaccines against infectious diseases and oncology benefiting from the proprietary platform technology of viral vaccines. It covers pre-clinical and clinical trials and the main indications targeted are smallpox, Ebola and respiratory syncytial virus (RSV) for infectious diseases and prostate, colorectal and breast cancer in oncology.


    Pharmaceutical research for and clinical development of new therapeutics, including vaccines and diagnostics is one of the most costly and risky activities of knowledge creation. Through its research, development and innovation (RDI) activities, the company is expected to contribute to the competitive search for and generation of new pharmaceutical knowledge in Europe in areas that are important for the improvement of its citizens' health. In particular due to its activities in infectious diseases, it contributes to the potential prevention of future pandemics.


    Proposed EIB finance (Approximate amount)

    EUR 50 million

    Total cost (Approximate amount)

    EUR 128 million

    Environmental aspects

    The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.


    The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having a status of a contracting entity, thus not being subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2004/17/EC), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2004/17/EC and Directive 92/13/EEC), with publication of tender notices in the EU Official Journal, as and where required.


    Signed - 12/05/2015


    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Germany Denmark Industry